Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 40

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 40
---
 — The Business Combination Proposal .”

Q:

Why is Iris proposing the Incentive Plan Proposal?

A:

The purpose of the Incentive Plan is to provide eligible employees, directors and consultants of ParentCo the opportunity to receive stock-based incentive awards in order to encourage such persons to contribute materially to the growth of ParentCo and align their economic interests with those of its stockholders.

Q:

What happens if I sell my shares of Iris common stock before the Special Meeting?

A:

The record date for the Special Meeting is , 2025, and is earlier than the date on which we expect the Business Combination to be completed. If you transfer your shares of Iris common stock after the record date, but before the Special Meeting, unless the transferee obtains a proxy from you to vote those shares, you will retain your right to vote at the Special Meeting. However, you will not be able to seek redemption of your shares because you will no longer be able to deliver them for cancellation upon consummation of the Business Combination. If you transfer your shares of Iris common stock before the record date, you will have no right to vote those shares at the Special Meeting or redeem those shares for a pro rata portion of the proceeds held in our Trust Account. Regardless of whether you transfer your shares of Iris common stock before or after the record date, your transferee will be entitled to exercise redemption rights with respect to the shares purchased by following the procedures set forth in this proxy statement/prospectus.

Q:**

#### When and where is the Special Meeting?
**A:

The Special Meeting will be held via live webcast on , 2025, at , Eastern Time. Iris will be holding the Special Meeting virtually at the following URL: .

Q:**

#### Who may vote at the Special Meeting?
A:

Only holders of record of our common stock as of the close of business on , 2025 (the “record date”) may vote at the Special Meeting. As of the close of business on the record date, there were 7,074,477 shares of Iris Class A Common Stock outstanding and entitled to vote. Our executive officers, directors and affiliates held approximately 98% of the voting power of our outstanding shares of Iris common stock, and all of such shares will be voted in favor of the Business Combination

<div align='center'>xiii</div>

TABLE OF CONTENTS

Proposal and other proposals described in this proxy statement/prospectus and presented at the Special Meeting pursuant to the Sponsor Agreement. For additional information,